TW202130631A - 3—(5—甲氧基—1—側氧基異吲哚啉—2—基)哌啶—2,6—二酮衍生物及其用途 - Google Patents

3—(5—甲氧基—1—側氧基異吲哚啉—2—基)哌啶—2,6—二酮衍生物及其用途 Download PDF

Info

Publication number
TW202130631A
TW202130631A TW109144481A TW109144481A TW202130631A TW 202130631 A TW202130631 A TW 202130631A TW 109144481 A TW109144481 A TW 109144481A TW 109144481 A TW109144481 A TW 109144481A TW 202130631 A TW202130631 A TW 202130631A
Authority
TW
Taiwan
Prior art keywords
alkyl
group
independently selected
piperidin
membered
Prior art date
Application number
TW109144481A
Other languages
English (en)
Chinese (zh)
Inventor
西蒙 波納茲
阿提恩 瑟尼堅科
珍妮弗 斯特羅卡 科步
納塔立 戴爾斯
約翰 萊恩 克立根
飛利浦 林
海斯南 艾美德 瑪利克
葛瑞 歐伯恩
安卓 W 派特森
尼爾 瑪瑞 法蘭斯 湯姆森
悅凡 丁
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202130631A publication Critical patent/TW202130631A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109144481A 2019-12-18 2020-12-16 3—(5—甲氧基—1—側氧基異吲哚啉—2—基)哌啶—2,6—二酮衍生物及其用途 TW202130631A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962950048P 2019-12-18 2019-12-18
US62/950,048 2019-12-18

Publications (1)

Publication Number Publication Date
TW202130631A true TW202130631A (zh) 2021-08-16

Family

ID=73856242

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109144481A TW202130631A (zh) 2019-12-18 2020-12-16 3—(5—甲氧基—1—側氧基異吲哚啉—2—基)哌啶—2,6—二酮衍生物及其用途

Country Status (23)

Country Link
US (1) US11566022B2 (cg-RX-API-DMAC7.html)
EP (1) EP4076650B1 (cg-RX-API-DMAC7.html)
JP (1) JP7682181B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220114065A (cg-RX-API-DMAC7.html)
CN (1) CN114828959B (cg-RX-API-DMAC7.html)
AR (1) AR120773A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020410514A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011796A2 (cg-RX-API-DMAC7.html)
CA (1) CA3164832A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022008243A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220278A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000121A (cg-RX-API-DMAC7.html)
EC (1) ECSP22055267A (cg-RX-API-DMAC7.html)
ES (1) ES2980575T3 (cg-RX-API-DMAC7.html)
IL (1) IL293530A (cg-RX-API-DMAC7.html)
JO (1) JOP20220152A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022007351A (cg-RX-API-DMAC7.html)
PE (1) PE20230159A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551482A1 (cg-RX-API-DMAC7.html)
PY (1) PY2084899A (cg-RX-API-DMAC7.html)
TW (1) TW202130631A (cg-RX-API-DMAC7.html)
UY (1) UY38986A (cg-RX-API-DMAC7.html)
WO (1) WO2021124172A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3186926A1 (en) * 2020-08-07 2022-02-10 Francis Barany Therapeutically useful cure-pro molecules for e3 ligase mediated degradation of proteins, and methods of making and using them
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
WO2022254362A1 (en) 2021-06-03 2022-12-08 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof
JP7744061B2 (ja) * 2021-07-30 2025-09-25 ヒノバ ファーマシューティカルズ インコーポレイテッド 二官能性キメラ複素環式化合物及びアンドロゲン受容体分解剤としての使用
US20240124412A1 (en) * 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途
EP4644382A4 (en) * 2022-12-27 2026-04-01 Gluetacs Therapeutics Shanghai Co Ltd ISOINDOLINONE SKELETON-BASED COMPOUND WITH SULFUR/OXYGEN SUBSTITUTED GLUTARIMIDE AND ITS USE
CN115959976A (zh) * 2022-12-30 2023-04-14 安徽诺全药业有限公司 一种甲氧基取代双环戊烷衍生物的制备方法
WO2024255810A1 (en) * 2023-06-15 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof
TW202530209A (zh) * 2023-10-06 2025-08-01 美商德爾菲亞治療股份有限公司 化合物、其醫藥組合物及其使用方法
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025137613A1 (en) * 2023-12-22 2025-06-26 Ganymede Oncology, Inc. Cycloalkylene nrf2 protein degraders
WO2026035999A1 (en) 2024-08-09 2026-02-12 Triana Biomedicines, Inc. Anaplastic lymphoma kinase (alk) degraders and uses thereof
CN120717945A (zh) * 2025-08-15 2025-09-30 泰迩生物医药泰州有限公司 一种(2r,4s)-n-boc-4-羟基哌啶-2-甲酸甲酯的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2004532616A (ja) 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖rna仲介遺伝子抑制
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012068512A1 (en) 2010-11-18 2012-05-24 Deuteria Pharmaceuticals Llc 3-deutero-pomalidomide
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2014018866A1 (en) 2012-07-27 2014-01-30 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
US20170038387A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
CN110753693A (zh) 2016-12-23 2020-02-04 阿尔维纳斯运营股份有限公司 Egfr蛋白水解靶向嵌合分子和相关使用方法
IL325835A (en) 2016-12-23 2026-03-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
IL300417A (en) 2017-01-26 2023-04-01 Arvinas Operations Inc Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
EP3676268A1 (en) 2017-10-20 2020-07-08 Dana-Farber Cancer Institute, Inc. Heterobifunctional compounds with improved specificityfor the bromodomain of brd4
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019177902A1 (en) 2018-03-10 2019-09-19 Yale University Modulators of btk proteolysis and methods of use
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
CA3095912A1 (en) 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
CA3102212A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds
AU2019294835B2 (en) 2018-06-29 2025-04-17 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (CRBN)
EP3814380A4 (en) 2018-06-29 2022-06-15 Dana Farber Cancer Institute, Inc. BISPECIFIC DEGRADATION PRODUCTS
US12030892B2 (en) 2018-06-29 2024-07-09 Dana-Farber Cancer Institute, Inc. CRBN modulators
CN113490495B (zh) 2018-12-03 2024-09-27 达纳-法伯癌症研究公司 Helios的小分子降解剂及其使用方法
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives

Also Published As

Publication number Publication date
CN114828959A (zh) 2022-07-29
AR120773A1 (es) 2022-03-16
EP4076650A1 (en) 2022-10-26
PH12022551482A1 (en) 2023-11-29
CN114828959B (zh) 2024-04-02
UY38986A (es) 2021-07-30
PY2084899A (es) 2021-09-23
ECSP22055267A (es) 2022-08-31
EP4076650B1 (en) 2024-02-28
AU2020410514A1 (en) 2022-06-30
DOP2022000121A (es) 2022-08-15
PE20230159A1 (es) 2023-02-01
WO2021124172A1 (en) 2021-06-24
MX2022007351A (es) 2022-07-19
US20220402904A1 (en) 2022-12-22
CO2022008243A2 (es) 2022-07-08
CR20220278A (es) 2022-07-01
US11566022B2 (en) 2023-01-31
JOP20220152A1 (ar) 2023-01-30
JP2023506642A (ja) 2023-02-17
BR112022011796A2 (pt) 2022-08-30
ES2980575T3 (es) 2024-10-02
JP7682181B2 (ja) 2025-05-23
KR20220114065A (ko) 2022-08-17
IL293530A (en) 2022-08-01
CA3164832A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CN114828959B (zh) 3-(5-甲氧基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CN103987707B (zh) 吡唑‑4‑基‑杂环基‑甲酰胺化合物以及使用方法
KR102505629B1 (ko) 알파 v 인테그린 억제제로서의 3-치환된 프로피온산
CN108440515B (zh) 取代的苯并呋喃基和苯并噁唑基化合物及其用途
CN104583196B (zh) 1,4-二取代的哒嗪类似物以及治疗与smn缺乏相关的病症的方法
CN105121426B (zh) 吡咯烷gpr40调节剂
CN104812748B (zh) 二氢吡唑gpr40调节剂
CN104918935B (zh) 二氢吡唑gpr40调节剂
CN115485278A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
JP2020040989A (ja) ブルトン型チロシンキナーゼ(btk)インヒビターとしての多フルオロ置換化合物
CN112566637A (zh) Glp-1受体激动剂及其用途
TW202308655A (zh) 膦醯衍生物及其組合物和藥學上的應用
CN104334557A (zh) 二酰基甘油酰基转移酶2抑制剂
TW201443023A (zh) 作爲rock抑制劑之酞□酮及異喹啉酮
JP2024505261A (ja) Cdk2阻害剤およびその使用方法
CN111527078A (zh) 吡啶羰基衍生物及其作为trpc 6抑制剂的治疗用途
JP2019518747A (ja) 大環状インドール誘導体
WO2023016518A1 (zh) 一种杂环衍生物及其组合物和药学上的应用
TW202333663A (zh) Rxfp1促效劑
WO2024217481A1 (zh) Egfr降解剂、其药物组合物及其用途
WO2025067239A1 (zh) 驱动蛋白kif18a抑制剂及其应用
WO2024094171A1 (zh) 取代的氨基嘧啶类化合物、其制备方法及其在医药上的应用
CN116940571A (zh) 苯并异噁唑衍生物及其用途
HK40063823A (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
HK40044822A (en) Glp-1 receptor agonists and uses thereof